Specifically, we focus on the different types of therapeutic agents available for the inhibition of the NLRP3 inflammasome and summarize pharmacological treatments for NAFLD involving NLRP3 blockade. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.